Published in Clin Exp Immunol on August 01, 1979
A comparative study of streptococcal antigen-binding human T8+ cells and monocytes, in relation to the HLA-DRw6 locus and the helper, suppressor and contrasuppressor functions. Immunology (1984) 1.00
Induction of human antigen-specific suppressor factors in vitro. Clin Exp Immunol (1981) 0.97
The role of a human antigen specific T8+ cell subset in antigen presentation, helper function and contrasuppression. Clin Exp Immunol (1985) 0.96
Immune response potential to poly(Tyr,Glu)-poly(DLAla)--poly(Lys) of human T cells of different donors. Proc Natl Acad Sci U S A (1981) 0.95
Antigen-specific T-cell factors. Immunology (1980) 0.89
Partial purification and characterization of an antigen-specific helper factor synthesized by a T-cell continuous line. Proc Natl Acad Sci U S A (1983) 0.83
Genetics of human T cell-monocyte interaction in helper cell induction. Clin Exp Immunol (1981) 0.75
Human insulin specific suppressor factors. I. Induction, characteristics and comparison to murine factors. Clin Exp Immunol (1982) 0.75
Histocompatibility-linked immune response genes. Science (1972) 16.79
Chemical coupling of proteins to agarose. Nature (1967) 10.52
Histocompatibility matching. VI. Miniaturization of the mixed leukocyte culture test: a preliminary report. Transplantation (1971) 5.43
Replacement of T-cell function by a T-cell product. Nat New Biol (1972) 5.20
Antigen-specific T-cell factor in cell cooperation. Mapping within the I region of the H-2 complex and ability to cooperate across allogeneic barriers. J Exp Med (1975) 4.64
Two genes in the major histocompatibility complex control immune response. Nature (1975) 4.08
Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin. J Exp Med (1972) 3.57
Activation of T and B lymphocytes in vitro. II. Biological and biochemical properties of an allogeneic effect factor (AEF) active in triggering specific B lymphocytes. J Exp Med (1974) 3.54
T cell factor which can replace T cells in vivo. Nature (1974) 3.10
The association between the HLA system and disease. Prog Med Genet (1977) 2.67
General method for the detection of cells producing antibodies against haptens and proteins. Nature (1970) 1.92
The specificity of T-cell helper factor in man. J Exp Med (1977) 1.68
Mode of action of a supernatant activity from T-cell cultures that nonspecifically stimulates the humoral immune response. Proc Natl Acad Sci U S A (1974) 1.57
Association between an HLA haplotype and low responsiveness to tetanus toxoid in man. Nature (1978) 1.56
Antigen-specific helper factor in man. J Exp Med (1978) 1.51
HL-A antigens and antibody response after influenza A vaccination. Decreased response associated with HL-A type W16. N Engl J Med (1976) 1.49
Human mixed lymphocyte cultures. Evaluation of a microculture technique utilizing the Multiple Automated Sample Harvester (MASH). Clin Exp Immunol (1973) 1.41
Current concepts of the antibody response: heterogeneity of lymphoid cells, interactions, and factors. Cold Spring Harb Symp Quant Biol (1977) 1.11
Induction of an antibody response in cultures of human peripheral blood lymphocytes. J Exp Med (1976) 1.04
Induction of human antigen-specific and non-specific helper factors in vitro. Clin Exp Immunol (1979) 1.03
In vitro studies on H-2 linked unresponsiveness. 1. Normal helper cells to (T,G)-A-L and GAT in low and non-responder mice. Immunology (1977) 0.99
Are the Ir genes expressed by macrophages? Nature (1977) 0.92
Detection of acceptor sites on human lymphocytes for antigen-specific T cell factors. Nature (1977) 0.86
The primed LD typing test: analysis of individuals immunized to GLT. Transplant Proc (1977) 0.78
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet (1983) 5.64
The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol (1973) 5.64
The role of macrophages in the generation of T-helper cells. II. The genetic control of the macrophage-T-cell interaction for helper cell induction with soluble antigens. J Exp Med (1975) 5.48
Correlation between subjective and objective evaluation of the nasal airway. A systematic review of the highest level of evidence. Clin Otolaryngol (2009) 5.33
The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum (1990) 5.09
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
A neural basis for general intelligence. Science (2000) 4.49
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (2000) 4.18
The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med (1971) 4.03
How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum (1990) 3.78
X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells. J Exp Med (1975) 3.70
Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin. J Exp Med (1972) 3.57
Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med (1983) 3.52
Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med (1975) 3.36
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) (1980) 3.20
Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol (1985) 3.18
Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature (1985) 3.11
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06
Separation of suppressor and killer T cells by surgace phenotype. Nature (1976) 3.03
HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature (1987) 2.96
The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ (1968) 2.96
Different Ly antigen phenotypes of in vitro induced helper and suppressor cells. Nature (1975) 2.91
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90
Dendritic cells induce T cell proliferation to synthetic antigens under Ir gene control. J Exp Med (1980) 2.88
Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol (1996) 2.85
Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A (1997) 2.80
Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology (2005) 2.79
Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull World Health Organ (1969) 2.77
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Serological studies in cholera. 3. Serum toxin neutralization--rise in titre in response to infection with Vibrio cholerae, and the level in the "normal" population of East Pakistan. Bull World Health Organ (1968) 2.71
Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry (2006) 2.65
T-cell lines producing antigen-specific suppressor factor. Nature (1978) 2.63
OMFS: Gender imbalance? Br Dent J (2016) 2.56
Surface immunoglobulin D as a functional receptor for a subclass of B lymphocytes. Immunol Rev (1977) 2.50
Cell interactions in the immune response in vitro. IV. Comparison of the effects of antigen-specific and allogeneic thymus-derived cell factors. J Exp Med (1972) 2.48
Unusual synovial fluid findings in Reiter's syndrome. Ann Intern Med (1967) 2.47
Tolerance, enhancement and the regulation of interactions between T cells, B cells and macrophages. Transplant Rev (1972) 2.44
B-lymphocyte heterogeneity: development and characterization of an alloantiserum which distinguishes B-lymphocyte differentiation alloantigens. J Exp Med (1977) 2.44
Modulation of cytokine production by transforming growth factor-beta. J Immunol (1989) 2.42
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
Hematological characterization of congenital osteopetrosis in op/op mouse. Possible mechanism for abnormal macrophage differentiation. J Exp Med (1982) 2.39
Apoptosis in rheumatoid arthritis synovium. J Clin Invest (1995) 2.39
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol (1992) 2.34
Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet (1998) 2.31
Breakdown products of C 3 in human synovial fluids. J Clin Invest (1969) 2.31
Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells. Science (1985) 2.27
A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer (2000) 2.27
Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27
Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther (2013) 2.26
T-T interactions in the induction of suppressor and helper T cells: analysis of membrane phenotype of precursor and amplifier cells. J Exp Med (1977) 2.22
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther (2014) 2.22
Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest (1976) 2.20
Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest (1989) 2.18
Antibody-mediated suppression of the immune response in vitro. I. Evidence for a central effect. J Exp Med (1970) 2.17
Cell-mediated immune response in vitro. II. The role of thymus and thymus-derived lymphocytes. Cell Immunol (1972) 2.15
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
Tolerance of T-cell clones is associated with membrane antigen changes. Nature (1983) 2.10
Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol (1992) 2.08
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06
The effect of magnesium sulphate infusion on the incidence and severity of emergence agitation in children undergoing adenotonsillectomy using sevoflurane anaesthesia. Anaesthesia (2013) 2.06
Suppressor cell induction in vitro. II. Cellular requirements of suppressor cell induction. Eur J Immunol (1976) 2.05
Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor. Arthritis Rheum (1987) 2.04
Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol (1998) 2.03
Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today (2000) 2.03
Relationship between antigen and antibody-induced suppression of immunity. Transplant Rev (1972) 2.02
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol (1990) 2.01
Rabbit anaphylactic antibody. J Exp Med (1966) 2.01
Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A (1998) 2.01
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol (1998) 1.96
Cell interactions in the immune response in vitro. 3. Specific collaboration across a cell impermeable membrane. J Exp Med (1972) 1.96
Antibody-mediated suppression of the immune response in vitro. II. A new approach to the phenomenon of immunological tolerance. J Exp Med (1970) 1.93
Estimating the true extent of cognitive decline in the old old. J Am Geriatr Soc (1999) 1.90
Cell-mediated immune response in vitro. 3. The requirement for macrophages in cytotoxic reactions against cell-bound and subcellular alloantigens. J Exp Med (1972) 1.89
Reactions of aggregated mercaptoethanol treated gamma globulin with rheumatoid factor--precipitin and complement fixation studies. Arthritis Rheum (1968) 1.88
Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 1.87
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87
Role of macrophages in in vitro induction of T-helper cells. Nature (1975) 1.84
Effect of murine cytomegalovirus on the in vitro responses of T and B cells to mitogens. J Immunol (1976) 1.84
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest (1994) 1.81